LMAT - Is This Under-the-Radar Medical Device Company a Post-Earnings Buy?
Medical device maker LeMaitre Vascular (NASDAQ: LMAT) delivered for shareholders in the second quarter, hitting analysts' revenue and earnings forecasts out of the park.
LeMaitre posted record second-quarter sales, beating analyst estimates of $38 million by 7.1%, and the company's diluted earnings per share (EPS) trounced expectations of $0.31 by 29%.
We'll look at the factors that helped LeMaitre to deliver strong financial results in the second quarter, whether the company's operating momentum can continue as the year unfolds, and LeMaitre's financial positioning to determine whether the company is an ideal post-earnings buy.
For further details see:
Is This Under-the-Radar Medical Device Company a Post-Earnings Buy?